Mesoblast’s (MESO) Buy Rating Reiterated at Maxim Group

Share on StockTwits

Maxim Group reiterated their buy rating on shares of Mesoblast (NASDAQ:MESO) in a research note released on Thursday morning, AnalystRatings.com reports. Maxim Group currently has a $16.00 price objective on the stock.

MESO has been the subject of several other reports. Chardan Capital set a $6.00 price target on Mesoblast and gave the company a hold rating in a report on Friday, August 30th. Zacks Investment Research cut Mesoblast from a buy rating to a hold rating in a report on Friday, September 6th. Oppenheimer set a $10.00 price target on Mesoblast and gave the company a buy rating in a report on Tuesday, September 10th. ValuEngine raised Mesoblast from a hold rating to a buy rating in a report on Tuesday, September 10th. Finally, Cantor Fitzgerald set a $23.00 price target on Mesoblast and gave the company a buy rating in a report on Tuesday, September 10th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Mesoblast presently has a consensus rating of Buy and an average target price of $11.25.

Shares of MESO traded up $0.48 during mid-day trading on Thursday, hitting $7.23. The company’s stock had a trading volume of 111,762 shares, compared to its average volume of 56,423. The company has a current ratio of 1.41, a quick ratio of 1.92 and a debt-to-equity ratio of 0.14. The firm has a 50-day simple moving average of $5.10 and a 200 day simple moving average of $5.10. The firm has a market capitalization of $635.65 million, a P/E ratio of -7.95 and a beta of 1.77. Mesoblast has a 1-year low of $3.35 and a 1-year high of $8.78.

Mesoblast (NASDAQ:MESO) last posted its quarterly earnings results on Thursday, August 29th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. The business had revenue of $1.97 million during the quarter, compared to analysts’ expectations of $1.31 million. Mesoblast had a negative return on equity of 17.66% and a negative net margin of 536.97%. As a group, sell-side analysts predict that Mesoblast will post -0.72 EPS for the current fiscal year.

An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley grew its stake in shares of Mesoblast limited (NASDAQ:MESO) by 284.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 147,702 shares of the company’s stock after buying an additional 109,295 shares during the period. Morgan Stanley owned 0.16% of Mesoblast worth $784,000 at the end of the most recent reporting period. 2.76% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Recommended Story: How prevalent are 12b-1 fees?

Analyst Recommendations for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

iShares Russell 1000 Growth ETF  Shares Sold by Acropolis Investment Management LLC
iShares Russell 1000 Growth ETF Shares Sold by Acropolis Investment Management LLC
Acropolis Investment Management LLC Sells 202 Shares of Deere & Company
Acropolis Investment Management LLC Sells 202 Shares of Deere & Company
Acropolis Investment Management LLC Cuts Stock Position in Schwab International Equity ETF
Acropolis Investment Management LLC Cuts Stock Position in Schwab International Equity ETF
PPL  Lifted to Hold at Zacks Investment Research
PPL Lifted to Hold at Zacks Investment Research
T-Mobile Us  Given a $88.00 Price Target by Barclays Analysts
T-Mobile Us Given a $88.00 Price Target by Barclays Analysts
Short Interest in Beyondspring Inc  Rises By 9.4%
Short Interest in Beyondspring Inc Rises By 9.4%


© 2006-2019 Ticker Report